α-PD1	anti-PD1
Ad5	adenovirus type 5;
Ad19 or Ad19a or Ad19a/64	adenovirus type 19a/64;
Adv	adenovirus;
BMDCs	bone marrow-derived dendritic cells;
BSA	bovine serum albumin;
CMV	cytomegalovirus promoter;
CTL	cytotoxic T lymphocyte;
CpG	cytosine-phosphate-guanine;
CPI	checkpoint inhibitor;
DC	dendritic cell;
ELISA	enzyme linked immunosorbent assay;
Env	envelope;
ERV	endogenous retrovirus;
FBS	foetal bovine serum;
Gag	group-specific antigen;
GM-CSF	granulocyte-macrophage colony stimulating factor;
HERV	human endogenous retrovirus;
HRP	horseradish peroxidase;
IFNγ	interferon gamma;
IFU	infectious units;
Ig	immunoglobulins;
IL	interleukin;
i.p.	intraperitoneal;
ICS	intracellular cytokine staining;
ISD	immunosuppressive domain;
ISDmut	immunosuppressive domain mutated;
ISDwt	immunosuppressive domain wild type;
LPS	lipopolysaccharide;
MCS	multiple cloning site;
MelARV	melanoma-associated retrovirus;
MOI	multiplicity of infection;
MuLV	murine leukaemia virus;
NaN3	sodium azide;
P2A	porcine teschovirus-1 2A peptide
PBS	phosphate buffered saline;
s.c.	subcutaneously;
SU	surface;
SV40-pA	simian virus 40 polyA;
TEM	transmission electron microscopy;
TNFα	tumour necrosis factor alpha;
TM	transmembrane or p15E;
UMI	unique molecular identifier
VLP	virus-like particle;
VLV	virus-like vaccine;
WB	Western blot;
wt	wild type.